Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Judge tears into ‘safe harbour’ ruling in heart valve system case
MedTech
Judge tears into ‘safe harbour’ ruling in heart valve system case
Judge’s dissenting opinion challenges the interpretation of the safe harbour provision by the US Court of Appeals for the Federal Circuit | Decision concerns Meril's importation of transcatheter heart valve systems in a dispute with Edwards Lifesciences | Court majority upheld the district court's ruling favouring Meril.   26 March 2024
PTAB grants BioNTech and Pfizer's inter partes review against Moderna
Pharma
PTAB grants BioNTech and Pfizer's inter partes review against Moderna
US Patent Trial and Appeal Board sides with the biotech pair in their challenge against Moderna's mRNA vaccine patents | Inter partes review challenges broad claims and monopolisation over mRNA tech.   21 March 2024
Raising the pulse: How Masimo v Apple changed patent strategy
MedTech
Raising the pulse: How Masimo v Apple changed patent strategy
The drama of the decade-long patent dispute reflects a changing market. Marisa Woutersen speaks with John Cronin and Pete Conley from Know Labs to explore its impact on patent strategy and the changing face of medtech.   5 March 2024
Biotech
Johnson & Johnson subsidiary tries to overthrow $20m verdict
DePuy Synthes tries to overturn a ruling over knee replacement device | Challenges the court's decision, including ownership disputes, interpretation of critical terms, and the granting of a permanent injunction.   27 February 2024
MedTech
Denneroll attempts to protect its chiropractic devices with new suit
Australia-based spinal orthotics device company files suit against ChiroLux | Alleges infringement of one of its chiropractic products aimed at relieving neck pain.   22 February 2024
Unified Patent Court
Free-to-use UPC cases portal launches
International membership organisation launches platform enabling access to UPC cases and statistics | Tool aims to provide transparency amidst concerns and latest decision requiring legal representation to request access to court documents | Life sciences cases take up two-thirds of UPC cases.   20 February 2024
Pharma
MSD can appeal SPC ruling due to 'wrongly decided' case
Judge says UK courts should depart from a European precedent following Brexit | MSD counsel says appeal had been granted due to courts' “ flip-flopping” on the precedent(s) set by the landmark cases Neurim and Santen.   15 February 2024
article
Pharma body attacks ‘vague’ march-in rights plan
PhRMA says controversial draft framework misinterprets the Bayh-Dole Act and could undo years of success | FTC unanimously supports the proposal.   8 February 2024
Americas
White & Case litigation partner who reps Gilead moves to Cahill Gordon & Reindel
Firm adds to its New York office with the appointment of ANDA expert as a partner in litigation group | Represented clients such as Gilead, Sanofi-Aventis, and Bristol-Myers Squibb in high-stakes cases.   1 February 2024
Americas
Pfizer and BioNTech allege inconsistencies in Moderna’s COVID-19 statements
Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions.   1 February 2024

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.